Bob Bradway, Amgen CEO (Justin Kase Conder/AP Images for Amgen)
Amgen chief Bradway nabs a rare disease player in $4B buyout as the M&A tempo accelerates
Amgen CEO Bob Bradway is bellying up to the M&A table today, scooping up the newly anointed commercial biotech ChemoCentryx $CCXI and its recently approved …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.